| Title |
Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
|
|---|---|
| Published in |
Advances in Therapy, March 2018
|
| DOI | 10.1007/s12325-018-0687-z |
| Pubmed ID | |
| Authors |
Carlo Cattaneo, Jaime Kulisevsky, Viviana Tubazio, Paola Castellani |
| Abstract |
Chronic pain is an important yet overlooked non-motor symptom of Parkinson's disease (PD), caused by an imbalance of the dopaminergic and glutamatergic systems. Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms. To investigate the long-term (2-year) efficacy of safinamide on PD chronic pain and to confirm the positive effects observed after 6 months of treatment. This is a post hoc analysis of the data from the 2-year study 018, focused on the reduction of concomitant pain treatments and on the scores of pain-related items of the Parkinson's disease quality of life questionnaire (PDQ-39). Safinamide, compared with placebo, significantly improved the PDQ-39 items 37 ("painful cramps or spasm," p = 0.0074) and 39 ("unpleasantly hot or cold," p = 0.0209) and significantly reduced the number of concomitant pain treatments by 26.2% (p = 0.005). A significantly greater proportion of patients in the safinamide group was not using pain drugs after 2 years of treatment (p = 0.0478). The positive effects of safinamide on PD chronic pain were maintained in the long term. Further investigations are desirable to confirm their clinical relevance. Zambon SpA. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 15% |
| Student > Master | 11 | 11% |
| Other | 7 | 7% |
| Student > Ph. D. Student | 7 | 7% |
| Researcher | 5 | 5% |
| Other | 14 | 14% |
| Unknown | 42 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 23% |
| Neuroscience | 12 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
| Psychology | 3 | 3% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 45 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2023.
All research outputs
#3,062,120
of 24,169,085 outputs
Outputs from Advances in Therapy
#275
of 2,483 outputs
Outputs of similar age
#63,037
of 337,473 outputs
Outputs of similar age from Advances in Therapy
#8
of 34 outputs
Altmetric has tracked 24,169,085 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,483 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,473 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.